Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2001 March;45(1) > The Quarterly Journal of Nuclear Medicine 2001 March;45(1):47-52

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

  NUCLEAR MEDICINE APPLICATIONS FOR BONE METASTASES 

The Quarterly Journal of Nuclear Medicine 2001 March;45(1):47-52

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography

Cook G. J. R., Fogelman I.

From the Department of Nuclear Medicine Royal Marsden Hospital, Sutton, Surrey, UK *Department of Nuclear Medicine Guys Hospital, London, UK


PDF


The use of posi­tron emis­sion tomog­ra­phy (PET) in clin­i­cal oncol­o­gy con­tin­ues to ­increase and ­although ­there is now a ­large lit­er­a­ture on the use of PET ­with var­i­ous trac­ers in a ­wide varie­ty of can­cers, ­there has pre­vi­ous­ly ­been rel­a­tive­ly lit­tle use spe­cif­i­cal­ly in the eval­u­a­tion of skel­e­tal metas­ta­ses. However, a num­ber of ­reports on PET in ­this ­area of oncol­o­gy are now becom­ing avail­able. The poten­tial advan­tag­es of PET ­over con­ven­tion­al nucle­ar med­i­cine tech­niques, includ­ing ­improved spa­tial res­o­lu­tion, abso­lute quan­ti­ta­tion and the acqui­si­tion of tom­o­graph­ic stud­ies as a rou­tine, are ­also of poten­tial ben­e­fit in ­this ­area. The ­bone ­agent, 18F-flu­o­ride and the ­tumour ­agent 18F-flu­o­rod­e­ox­y­glu­cose, ­have ­been ­used to eval­u­ate ­both ­benign and malig­nant skel­e­tal dis­or­ders qual­ita­tive­ly and quan­ti­ta­tive­ly and the cur­rent knowl­edge ­with ­respect to the skele­ton in can­cer ­patients is sum­mar­ised in ­this arti­cle.

inizio pagina